T1	DISO 1 17	Microalbuminuria
#1	AnnotatorNotes T1	C0730345; Microalbuminuria; Finding
T2	CHEM 33 45	paricalcitol
#2	AnnotatorNotes T2	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T3	DISO 70 94	enfermedad renal crónica
#3	AnnotatorNotes T3	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T4	DISO 121 132	albuminuria
#4	AnnotatorNotes T4	C0001925; Albuminuria; Finding
T5	DISO 171 190	insuficiencia renal
#5	AnnotatorNotes T5	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T6	CHEM 231 286	inhibidores del sistema renina-angiotensina-aldosterona
#6	AnnotatorNotes T6	C5240314; Substance with renin-angiotensin system inhibitor mechanism of action; Pharmacologic Substance
T7	ANAT 247 286	sistema renina-angiotensina-aldosterona
#7	AnnotatorNotes T7	C0086907; Renin-Angiotensin-Aldosterone System; Body System
T8	ANAT 288 292	SRAA
#8	AnnotatorNotes T8	C0086907; Renin-Angiotensin-Aldosterone System; Body System
T9	DISO 360 371	albuminuria
#9	AnnotatorNotes T9	C0001925; Albuminuria; Finding
T10	DISO 685 687	IR
#10	AnnotatorNotes T10	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T11	PROC 600 622	determinar la utilidad
T12	DISO 520 531	albuminuria
#11	AnnotatorNotes T12	C0001925; Albuminuria; Finding
T13	PROC 761 769	consulta
#12	AnnotatorNotes T13	C0009818; Consultation; Health Care Activity
T14	DISO 656 667	albuminuria
#13	AnnotatorNotes T14	C0001925; Albuminuria; Finding
T15	CHEM 469 481	paricalcitol
#14	AnnotatorNotes T15	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T16	CHEM 627 639	paricalcitol
#15	AnnotatorNotes T16	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T17	PROC 1051 1055	MDRD
#16	AnnotatorNotes T17	C1980036; Creatinine-based formula (MDRD); Laboratory Procedure
T18	PROC 971 980	consultas
#17	AnnotatorNotes T18	C0009818; Consultation; Health Care Activity
T19	CHEM 801 813	paricalcitol
#18	AnnotatorNotes T19	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T20	CHEM 905 911	calcio
#19	AnnotatorNotes T20	C0006675; calcium; Pharmacologic Substance · Biologically Active Substance · Element, Ion, or Isotope
T21	CHEM 912 919	fósforo
#20	AnnotatorNotes T21	C0031705; phosphorus; Element, Ion, or Isotope
T22	PROC 933 944	seguimiento
#21	AnnotatorNotes T22	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T23	CHEM 1035 1041	calcio
#22	AnnotatorNotes T23	C0006675; calcium; Pharmacologic Substance · Biologically Active Substance · Element, Ion, or Isotope
T24	CHEM 1042 1049	fósforo
#23	AnnotatorNotes T24	C0031705; phosphorus; Element, Ion, or Isotope
T25	DISO 1058 1069	albuminuria
#24	AnnotatorNotes T25	C0001925; Albuminuria; Finding
T26	PROC 1074 1085	tratamiento
#25	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	ANAT 1106 1110	SRAA
#26	AnnotatorNotes T27	C0086907; Renin-Angiotensin-Aldosterone System; Body System
T28	CHEM 1113 1123	hidroferol
#27	AnnotatorNotes T28	C1451832; Hidroferol; Organic Chemical · Pharmacologic Substance · Vitamin
T29	PROC 1498 1502	MDRD
#28	AnnotatorNotes T29	C1980036; Creatinine-based formula (MDRD); Laboratory Procedure
T30	PROC 1570 1574	UACR
#29	AnnotatorNotes T30	C0455271; Urine albumin/creatinine ratio measurement; Laboratory Procedure
T31	PROC 1731 1735	PTHi
#30	AnnotatorNotes T31	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T32	PROC 1416 1427	seguimiento
#31	AnnotatorNotes T32	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T33	DISO 1459 1470	hipertensos
#32	AnnotatorNotes T33	C0020538; Hypertensive disease; Disease or Syndrome
T34	DISO 1479 1489	diabéticos
#33	AnnotatorNotes T34	C0011849; Diabetes Mellitus; Disease or Syndrome | C0241863; Diabetic; Finding | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T35	CHEM 1560 1568	albúmina
#34	AnnotatorNotes T35	C0001924; Albumins; Amino Acid, Peptide, or Protein · Biologically Active Substance
T36	CHEM 1639 1645	calcio
#35	AnnotatorNotes T36	C0006675; calcium; Pharmacologic Substance · Biologically Active Substance · Element, Ion, or Isotope
T37	CHEM 1646 1653	fósforo
#36	AnnotatorNotes T37	C0031705; phosphorus; Element, Ion, or Isotope
T38	PROC 1708 1729	paratohormona intacta
#37	AnnotatorNotes T38	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T39	PROC 2360 2364	UACR
#38	AnnotatorNotes T39	C0455271; Urine albumin/creatinine ratio measurement; Laboratory Procedure
T40	PROC 1769 1780	seguimiento
#39	AnnotatorNotes T40	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T41	CHEM 1798 1849	inhibidores de la enzima conversora de angiotensina
#40	AnnotatorNotes T41	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T42	PROC 2795 2799	UACR
#41	AnnotatorNotes T42	C0455271; Urine albumin/creatinine ratio measurement; Laboratory Procedure
T43	PROC 2552 2556	UACR
#42	AnnotatorNotes T43	C0455271; Urine albumin/creatinine ratio measurement; Laboratory Procedure
T44	CHEM 1918 1928	hidroferol
#43	AnnotatorNotes T44	C1451832; Hidroferol; Organic Chemical · Pharmacologic Substance · Vitamin
T45	CHEM 1940 1950	calcitriol
#44	AnnotatorNotes T45	C0006674; calcitriol; Organic Chemical · Pharmacologic Substance · Vitamin | C3714610; Calcitriol Drug Class; Pharmacologic Substance · Vitamin
T46	PROC 1963 1974	seguimiento
#45	AnnotatorNotes T46	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T47	PROC 2110 2116	calcio
#46	AnnotatorNotes T47	C0201925; Calcium measurement; Laboratory Procedure
T48	DISO 3862 3883	riesgo cardiovascular
#47	AnnotatorNotes T48	C4324389; Cardiovascular Risk; Finding
T49	DISO 2715 2726	albuminuria
#48	AnnotatorNotes T49	C0001925; Albuminuria; Finding
T50	DISO 2757 2769	albuminurias
#49	AnnotatorNotes T50	C0001925; Albuminuria; Finding
T51	PROC 2826 2837	tratamiento
#50	AnnotatorNotes T51	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T52	ANAT 2858 2862	SRAA
#51	AnnotatorNotes T52	C0086907; Renin-Angiotensin-Aldosterone System; Body System
T53	CHEM 2864 2874	hidroferol
#52	AnnotatorNotes T53	C1451832; Hidroferol; Organic Chemical · Pharmacologic Substance · Vitamin
T54	CHEM 2878 2888	calcitriol
#53	AnnotatorNotes T54	C0006674; calcitriol; Organic Chemical · Pharmacologic Substance · Vitamin | C3714610; Calcitriol Drug Class; Pharmacologic Substance · Vitamin
T55	PROC 2923 2947	suspender el tratamiento
#54	AnnotatorNotes T55	C0850893; stop medication; Therapeutic or Preventive Procedure
T56	CHEM 2981 2987	calcio
#55	AnnotatorNotes T56	C0006675; calcium; Pharmacologic Substance · Biologically Active Substance · Element, Ion, or Isotope
T57	CHEM 2988 2995	fósforo
#56	AnnotatorNotes T57	C0031705; phosphorus; Element, Ion, or Isotope
T58	DISO 2998 3017	efectos secundarios
#57	AnnotatorNotes T58	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T59	PROC 3107 3118	tratamiento
#58	AnnotatorNotes T59	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T60	PROC 3193 3221	control del metabolismo óseo
T61	ANAT 3217 3221	óseo
#59	AnnotatorNotes T61	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T62	PROC 3267 3271	UACR
#60	AnnotatorNotes T62	C0455271; Urine albumin/creatinine ratio measurement; Laboratory Procedure
T63	CHEM 3350 3358	albúmina
#61	AnnotatorNotes T63	C0001924; Albumins; Amino Acid, Peptide, or Protein · Biologically Active Substance
T64	CHEM 3444 3452	albúmina
#62	AnnotatorNotes T64	C0001924; Albumins; Amino Acid, Peptide, or Protein · Biologically Active Substance
T65	PROC 3653 3664	tratamiento
#63	AnnotatorNotes T65	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T66	ANAT 3869 3883	cardiovascular
#64	AnnotatorNotes T66	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T67	CHEM 3943 3955	paricalcitol
#65	AnnotatorNotes T67	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T68	DISO 3988 3999	proteinuria
#66	AnnotatorNotes T68	C0033687; Proteinuria; Finding
T69	DISO 4082 4112	hiperparatiroidismo secundario
#67	AnnotatorNotes T69	C0020503; Hyperparathyroidism, Secondary; Disease or Syndrome
T70	PROC 4132 4142	prevención
#68	AnnotatorNotes T70	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T71	ANAT 81 86	renal
#69	AnnotatorNotes T71	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T72	ANAT 185 190	renal
#70	AnnotatorNotes T72	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T73	DISO 401 403	IR
#71	AnnotatorNotes T73	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T74	PROC 3921 3925	UACR
#72	AnnotatorNotes T74	C0455271; Urine albumin/creatinine ratio measurement; Laboratory Procedure
T75	DISO 4017 4027	IR crónica
#73	AnnotatorNotes T75	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T76	DISO 4166 4168	IR
#74	AnnotatorNotes T76	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T77	ANAT 3764 3769	renal
#75	AnnotatorNotes T77	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T78	PROC 2016 2020	MDRD
#76	AnnotatorNotes T78	C1980036; Creatinine-based formula (MDRD); Laboratory Procedure
T79	PROC 995 1049	registrándose variables del metabolismo calcio-fósforo
T80	CHEM 1090 1110	inhibidores del SRAA
#77	AnnotatorNotes T80	C5240314; Substance with renin-angiotensin system inhibitor mechanism of action; Pharmacologic Substance
T81	PROC 1532 1568	excreción urinaria media de albúmina
#78	AnnotatorNotes T81	C0455271; Urine albumin/creatinine ratio measurement; Laboratory Procedure
T82	DISO 3516 3518	IR
#79	AnnotatorNotes T82	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T83	PROC 1662 1668	calcio
#80	AnnotatorNotes T83	C0201925; Calcium measurement; Laboratory Procedure
T84	PROC 1687 1694	fósforo
#81	AnnotatorNotes T84	C0202178; Phosphorus measurement; Laboratory Procedure
T85	CHEM 1860 1909	antagonistas de los receptores de angiotensina II
#82	AnnotatorNotes T85	C0521942; Angiotensin II receptor antagonist; Pharmacologic Substance
T86	PROC 2088 2092	PTHi
#83	AnnotatorNotes T86	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T87	PROC 2266 2273	fósforo
#84	AnnotatorNotes T87	C0202178; Phosphorus measurement; Laboratory Procedure
T88	CHEM 2842 2862	inhibidores del SRAA
#85	AnnotatorNotes T88	C5240314; Substance with renin-angiotensin system inhibitor mechanism of action; Pharmacologic Substance
T89	DISO 2952 2995	alteraciones del metabolismo calcio-fósforo
T90	CHEM 3123 3135	paricalcitol
#86	AnnotatorNotes T90	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T91	DISO 3743 3769	deterioro de función renal
#87	AnnotatorNotes T91	C0341677; Impaired renal function disorder; Disease or Syndrome
T92	DISO 192 194	IR
#88	AnnotatorNotes T92	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T93	Duration 87 94	crónica
#89	AnnotatorNotes T93	C0205191; chronic; Temporal Concept
T95	Date 452 465	Recientemente
T96	LIVB 553 562	pacientes
#90	AnnotatorNotes T96	C0030705; Patients; Patient or Disabled Group
T97	LIVB 671 680	pacientes
#91	AnnotatorNotes T97	C0030705; Patients; Patient or Disabled Group
T98	LIVB 736 745	pacientes
#92	AnnotatorNotes T98	C0030705; Patients; Patient or Disabled Group
T99	Time 770 781	prediálisis
T100	Dose 838 848	1 ± 0,3 μg
T101	Frequency 848 852	/día
T102	Route 857 865	vía oral
#93	AnnotatorNotes T102	C1527415; Oral Route of Drug administration; Functional Concept
T103	PHYS 893 919	metabolismo calcio-fósforo
#94	AnnotatorNotes T103	C0596236; calcium metabolism; Organism Function + C0597223; phosphorus metabolism; Molecular Function
T104	Duration 948 964	al menos 6 meses
T105	Frequency 981 993	cada 2 meses
T106	PHYS 1023 1049	metabolismo calcio-fósforo
#95	AnnotatorNotes T106	C0596236; calcium metabolism; Organism Function + C0597223; phosphorus metabolism; Molecular Function
T108	LIVB 1385 1394	pacientes
#96	AnnotatorNotes T108	C0030705; Patients; Patient or Disabled Group
T109	Duration 1431 1443	135-235 días
T112	PHYS 1532 1550	excreción urinaria
#97	AnnotatorNotes T112	C0042034; Urination; Organism Function | C2371165; Urination functions; Organ or Tissue Function
T115	PHYS 1627 1653	metabolismo calcio-fósforo
#98	AnnotatorNotes T115	C0596236; calcium metabolism; Organism Function + C0597223; phosphorus metabolism; Molecular Function
T124	LIVB 2532 2541	pacientes
#99	AnnotatorNotes T124	C0030705; Patients; Patient or Disabled Group
T126	LIVB 2681 2690	pacientes
#100	AnnotatorNotes T126	C0030705; Patients; Patient or Disabled Group
T131	Neg_cue 2893 2899	ningún
T132	LIVB 2900 2908	paciente
#101	AnnotatorNotes T132	C0030705; Patients; Patient or Disabled Group
T133	PHYS 2969 2995	metabolismo calcio-fósforo
#102	AnnotatorNotes T133	C0596236; calcium metabolism; Organism Function + C0597223; phosphorus metabolism; Molecular Function
T134	LIVB 3154 3163	pacientes
#103	AnnotatorNotes T134	C0030705; Patients; Patient or Disabled Group
T135	PHYS 3205 3221	metabolismo óseo
#104	AnnotatorNotes T135	C0596204; bone metabolism; Organ or Tissue Function
T136	LIVB 3303 3312	pacientes
#105	AnnotatorNotes T136	C0030705; Patients; Patient or Disabled Group
T137	PHYS 3337 3346	excreción
#106	AnnotatorNotes T137	C0221102; Excretory function; Physiologic Function
T138	LIVB 3403 3412	pacientes
#107	AnnotatorNotes T138	C0030705; Patients; Patient or Disabled Group
T139	PHYS 3423 3432	excreción
#108	AnnotatorNotes T139	C0221102; Excretory function; Physiologic Function
T141	LIVB 3535 3544	pacientes
#109	AnnotatorNotes T141	C0030705; Patients; Patient or Disabled Group
T148	LIVB 4003 4012	pacientes
#110	AnnotatorNotes T148	C0030705; Patients; Patient or Disabled Group
T149	Duration 4020 4027	crónica
#111	AnnotatorNotes T149	C0205191; chronic; Temporal Concept
T94	LIVB 1400 1407	varones
#112	AnnotatorNotes T94	C0025266; Male population group; Population Group
T107	PROC 3053 3068	ajuste de dosis
#113	AnnotatorNotes T107	C2826232; Dose Adjustment; Health Care Activity
T110	Observation 384 394	progresión
#114	AnnotatorNotes T110	C1457868; Worse; Finding
T111	Observation 154 164	progresión
#115	AnnotatorNotes T111	C1457868; Worse; Finding
T113	Spec_cue 144 153	riesgo de
T114	Observation 4149 4159	progresión
#116	AnnotatorNotes T114	C1457868; Worse; Finding
T116	Observation 3499 3509	progresión
#117	AnnotatorNotes T116	C1457868; Worse; Finding
T117	Spec_cue 3489 3498	riesgo de
T118	PHYS 3756 3769	función renal
#118	AnnotatorNotes T118	C0232804; Renal function; Organ or Tissue Function
A1	Assertion T132 Negated
A2	Assertion T55 Negated
A3	Assertion T89 Negated
A4	Assertion T58 Negated
A5	Assertion T111 Speculated
A6	Assertion T116 Speculated
R1	Speculation Arg1:T113 Arg2:T111	
R2	Negation Arg1:T131 Arg2:T132	
R3	Negation Arg1:T131 Arg2:T55	
R4	Negation Arg1:T131 Arg2:T89	
R5	Negation Arg1:T131 Arg2:T58	
R6	Speculation Arg1:T117 Arg2:T116	
T119	CONC 1139 1146	cambios
A7	Assertion T119 Negated
#119	AnnotatorNotes T119	C0443172; Changed status; Quantitative Concept
T120	Neg_cue 1135 1138	sin
R7	Negation Arg1:T120 Arg2:T119	
T121	Neg_cue 2800 2802	no
T122	CONC 2803 2818	se correlacionó
A8	Assertion T122 Negated
#120	AnnotatorNotes T122	C1707520; Correlation; Qualitative Concept
R8	Negation Arg1:T121 Arg2:T122	
T123	Neg_cue 2278 2280	no
T125	CONC 2289 2314	significación estadística
A9	Assertion T125 Negated
#121	AnnotatorNotes T125	C0237881; Statistical Significance; Quantitative Concept
R9	Negation Arg1:T123 Arg2:T125	
T127	Spec_cue 3687 3702	posiblemente no
T128	CONC 3717 3724	control
A10	Assertion T128 Speculated
R10	Negation Arg1:T127 Arg2:T128	
T129	Spec_cue 3545 3550	puede
T130	Quantifier_or_Qualifier 3567 3579	insuficiente
A11	Assertion T130 Speculated
T142	Quantifier_or_Qualifier 3966 3972	eficaz
#122	AnnotatorNotes T142	C1704419; Effective; Qualitative Concept
R12	Has_Quantifier_or_Qualifier Arg1:T67 Arg2:T142	
R13	Location_of Arg1:T71 Arg2:T3	
R14	Has_Duration_or_Interval Arg1:T3 Arg2:T93	
T143	Quantifier_or_Qualifier 95 103	avanzada
#123	AnnotatorNotes T143	C0205179; Advanced phase; Qualitative Concept
R15	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T143	
R16	Before Arg1:T4 Arg2:T111	
R18	Before Arg1:T5 Arg2:T111	
R19	Before Arg1:T92 Arg2:T111	
R20	Location_of Arg1:T72 Arg2:T5	
R21	Location_of Arg1:T72 Arg2:T92	
T145	Quantifier_or_Qualifier 207 225	estadios avanzados
R22	Has_Quantifier_or_Qualifier Arg1:T92 Arg2:T145	
R23	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T145	
#125	AnnotatorNotes T145	C0205179; Advanced phase; Qualitative Concept
R24	Overlap Arg1:T4 Arg2:T5	
R25	Overlap Arg1:T4 Arg2:T92	
R27	Before Arg1:T73 Arg2:T110	
R28	Overlap Arg1:T9 Arg2:T73	
R31	Overlap Arg1:T15 Arg2:T95	
R34	Experiences Arg1:T96 Arg2:T15	
R35	Experiences Arg1:T96 Arg2:T12	
R36	Experiences Arg1:T97 Arg2:T10	
R37	Experiences Arg1:T97 Arg2:T14	
R38	Experiences Arg1:T97 Arg2:T16	
T151	Quantifier_or_Qualifier 691 700	grado 4-5
R39	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T151	
R42	Overlap Arg1:T14 Arg2:T10	
R43	Overlap Arg1:T13 Arg2:T99	
R44	Has_Dose_or_Strength Arg1:T19 Arg2:T100	
R45	Has_Frequency Arg1:T19 Arg2:T101	
R46	Has_Route_or_Mode Arg1:T19 Arg2:T102	
R47	Used_for Arg1:T20 Arg2:T103	
R48	Used_for Arg1:T21 Arg2:T103	
R49	Used_for Arg1:T23 Arg2:T106	
R50	Used_for Arg1:T24 Arg2:T106	
R52	Has_Duration_or_Interval Arg1:T22 Arg2:T104	
R53	Has_Frequency Arg1:T18 Arg2:T105	
R57	Has_Frequency Arg1:T79 Arg2:T105	
R58	Has_Frequency Arg1:T17 Arg2:T105	
R61	Used_for Arg1:T80 Arg2:T26	
R62	Used_for Arg1:T28 Arg2:T26	
T153	CONC 1171 1191	análisis de varianza
#130	AnnotatorNotes T153	C0002780; Analysis of Variance; Quantitative Concept
T154	CONC 1247 1263	test de Wilcoxon
#131	AnnotatorNotes T154	C0242931; Wilcoxon Rank Test; Quantitative Concept
T155	CONC 1295 1305	test de χ2
#132	AnnotatorNotes T155	C0008041; Chi-Square Test; Intellectual Product
R63	Has_Duration_or_Interval Arg1:T32 Arg2:T109	
T156	Quantifier_or_Qualifier 1503 1508	basal
#133	AnnotatorNotes T156	C1442488; Baseline; Quantitative Concept
R64	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T156	
R67	Used_for Arg1:T36 Arg2:T115	
R68	Used_for Arg1:T37 Arg2:T115	
T157	CONC 1758 1780	inicio del seguimiento
R69	Overlap Arg1:T41 Arg2:T157	
R70	Overlap Arg1:T85 Arg2:T157	
R71	Overlap Arg1:T44 Arg2:T157	
R72	Overlap Arg1:T45 Arg2:T157	
T158	Observation 2098 2116	aumento del calcio
#134	AnnotatorNotes T158	C0553702; Ca++ increased; Finding
T159	Observation 2073 2092	descenso de la PTHi
#135	AnnotatorNotes T159	C0856879; Parathyroid hormone decreased; Finding
R74	Overlap Arg1:T46 Arg2:T78	
T161	Observation 2254 2273	aumento del fósforo
#136	AnnotatorNotes T161	C0919625; Blood phosphorus increased; Finding (?) | C4715930; Increase in serum phosphorus; Finding (?)
T162	Observation 2360 2374	UACR disminuyó
#137	AnnotatorNotes T162	C1096059; Urine albumin/creatinine ratio decreased; Finding
R80	Experiences Arg1:T124 Arg2:T43	
R81	Experiences Arg1:T126 Arg2:T49	
T163	Result_or_Value 2695 2708	normalización
#138	AnnotatorNotes T163	C0459422; Normal result; Finding | C0586624; Normal laboratory finding; Finding
R85	Experiences Arg1:T126 Arg2:T50	
R87	Used_for Arg1:T88 Arg2:T51	
R88	Used_for Arg1:T53 Arg2:T51	
R89	Used_for Arg1:T54 Arg2:T51	
R90	Before Arg1:T89 Arg2:T55	
R91	Before Arg1:T58 Arg2:T55	
R92	Causes Arg1:T133 Arg2:T89	
R93	Used_for Arg1:T56 Arg2:T133	
R94	Used_for Arg1:T57 Arg2:T133	
R95	Experiences Arg1:T132 Arg2:T55	
R96	Experiences Arg1:T132 Arg2:T89	
R97	Experiences Arg1:T132 Arg2:T58	
R98	Experiences Arg1:T132 Arg2:T133	
R99	Experiences Arg1:T132 Arg2:T107	
R100	Before Arg1:T58 Arg2:T107	
R101	Before Arg1:T89 Arg2:T107	
R102	Experiences Arg1:T134 Arg2:T59	
R103	Used_for Arg1:T90 Arg2:T59	
R105	Location_of Arg1:T61 Arg2:T135	
R106	Location_of Arg1:T61 Arg2:T60	
R107	Experiences Arg1:T134 Arg2:T60	
R108	Experiences Arg1:T134 Arg2:T135	
T165	Observation 3238 3246;3261 3271	descenso de la UACR
#140	AnnotatorNotes T165	C1096059; Urine albumin/creatinine ratio decreased; Finding
R110	Has_Result_or_Value Arg1:T62 Arg2:T165	
R111	Experiences Arg1:T134 Arg2:T165	
R112	Experiences Arg1:T134 Arg2:T62	
R113	Overlap Arg1:T59 Arg2:T165	
R114	Experiences Arg1:T136 Arg2:T137	
R115	Used_for Arg1:T63 Arg2:T137	
R116	Experiences Arg1:T136 Arg2:T62	
R117	Experiences Arg1:T136 Arg2:T165	
R118	Experiences Arg1:T136 Arg2:T60	
R119	Experiences Arg1:T136 Arg2:T135	
R120	Experiences Arg1:T136 Arg2:T59	
T166	Observation 3317 3358	normalización de la excreción de albúmina
R121	Experiences Arg1:T136 Arg2:T166	
R123	Experiences Arg1:T134 Arg2:T137	
R124	Experiences Arg1:T134 Arg2:T166	
T167	Observation 3363 3369	efecto
#142	AnnotatorNotes T167	C1518681; Outcome of Therapy; Finding (?)
R125	Experiences Arg1:T138 Arg2:T167	
R126	Experiences Arg1:T138 Arg2:T139	
R127	Used_for Arg1:T64 Arg2:T139	
R128	Experiences Arg1:T138 Arg2:T116	
R129	Experiences Arg1:T138 Arg2:T82	
R130	Before Arg1:T82 Arg2:T116	
R131	Experiences Arg1:T141 Arg2:T65	
T168	Observation 3625 3648	efecto antiproteinúrico
R132	Causes Arg1:T65 Arg2:T168	
R133	Experiences Arg1:T141 Arg2:T168	
R134	Speculation Arg1:T129 Arg2:T130	
T169	Observation 3525 3544	número de pacientes
#143	AnnotatorNotes T169	C2360800; Number of patients; Finding
R135	Has_Quantifier_or_Qualifier Arg1:T169 Arg2:T130	
R136	Location_of Arg1:T77 Arg2:T118	
R137	Location_of Arg1:T77 Arg2:T91	
R139	Location_of Arg1:T66 Arg2:T48	
T170	Observation 3903 3925	disminución de la UACR
#144	AnnotatorNotes T170	C1096059; Urine albumin/creatinine ratio decreased; Finding
R143	Experiences Arg1:T148 Arg2:T68	
R144	Experiences Arg1:T148 Arg2:T75	
R145	Has_Duration_or_Interval Arg1:T75 Arg2:T149	
T172	Quantifier_or_Qualifier 4031 4040	grado 4-5
R146	Has_Quantifier_or_Qualifier Arg1:T75 Arg2:T172	
R147	Experiences Arg1:T148 Arg2:T67	
R153	Overlap Arg1:T75 Arg2:T69	
R154	Overlap Arg1:T68 Arg2:T75	
R155	Overlap Arg1:T68 Arg2:T69	
R156	Before Arg1:T70 Arg2:T114	
R157	Before Arg1:T76 Arg2:T114	
A12	Assertion T70 Speculated
T140	Spec_cue 4169 4189	necesita confirmarse
R11	Speculation Arg1:T140 Arg2:T70	
T144	Quantifier_or_Qualifier 3247 3260	significativo
#124	AnnotatorNotes T144	C0750502; Significant; Idea or Concept
R17	Has_Quantifier_or_Qualifier Arg1:T165 Arg2:T144	
R26	Overlap Arg1:T59 Arg2:T166	
#126	AnnotatorNotes T130	C0231180; Insufficient (qualifier); Qualitative Concept
T146	Quantifier_or_Qualifier 3725 3738	significativo
A13	Assertion T146 Speculated
#127	AnnotatorNotes T146	C0750502; Significant; Idea or Concept
R29	Has_Quantifier_or_Qualifier Arg1:T128 Arg2:T146	
R30	Speculation Arg1:T127 Arg2:T146	
#128	AnnotatorNotes T95	C0332185; Recent; Temporal Concept
#129	AnnotatorNotes T89	C0268076; DISORDERS OF PHOSPHORUS AND CALCIUM METABOLISM; Disease or Syndrome
A14	Experiencer T96 Patient
A15	Experiencer T97 Patient
A16	Experiencer T98 Patient
A17	Experiencer T108 Patient
A18	Experiencer T94 Patient
A19	Experiencer T124 Patient
A20	Experiencer T126 Patient
A21	Experiencer T132 Patient
A22	Experiencer T134 Patient
A23	Experiencer T136 Patient
A24	Experiencer T138 Patient
A25	Experiencer T141 Patient
A26	Experiencer T148 Patient
R32	Has_Result_or_Value Arg1:T86 Arg2:T159	
R33	Has_Result_or_Value Arg1:T47 Arg2:T158	
R40	Has_Result_or_Value Arg1:T87 Arg2:T161	
R41	Has_Result_or_Value Arg1:T39 Arg2:T162	
R51	Has_Result_or_Value Arg1:T74 Arg2:T170	
R54	Has_Result_or_Value Arg1:T49 Arg2:T163	
